Reference price systems: stakeholder dialogue and involvement
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 3
Abstract
Dylst et al. provide a detailed overview about the characteristics of reference price systems in Europe and discuss their possible impact. The role of stakeholders in the implementation of this policy measure requires further attention.
Authors and Affiliations
Sabine Vogler
Keywords
Related Articles
- EP ID EP355637
- DOI 10.5639/gabij.2012.0103-4.031
- Views 110
- Downloads 0
What to look forward to in GaBI Journal, 2012, issue 2
It is my pleasure to introduce the second edition of GaBI Journalwhich contains a number of interesting articles. Professors Benjamin and Kearns present a review of advances in paediatric drug development and labelling,...
Clinical development, immunogenicity, and interchangeability of follow-on complex drugs
Although not derived from living sources, non-biological complex drug (NBCD) products have the immunogenicity and molecular complexity of biological drugs. NBCDs typically contain heterogenous mixtures of closely related...
Drug shortages hit US oncologists hard
The number of drug shortages in the US has tripled between 2006 and 2012, with drug shortages now affecting most US oncologists and impacting on patient care. There is a need for new guidelines to control drug substituti...
Biologicals and biosimilars: a review of the science and its implications
Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory requirements fo...
Licensing and prescribing biosimilars in Australia
Some years ago, Australian regulatory authorities decided to follow the path laid down by the European Medicines Agency in adopting a process for approval of biosimilars. This has been a largely successful process, resul...